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OpinionAmong the hundreds of oncogenes and tumor suppres-
sors that have been identified in the past 50 years, p53 is
probably the best characterized; nevertheless, new func-
tions are constantly being discovered. As a tumor sup-
pressor, p53 regulates cellular responses to different
stress stimuli by inducing reversible cell cycle arrest
and DNA repair, or triggering senescence or apoptosis.
Recent findings on the regulation of stem cell (SC)
division and reprogramming suggest the intriguing pos-
sibility that p53 also carries out its tumor suppression
function by regulating SC homeostasis. Specifically, p53
activation may counteract SC expansion by several
emerging mechanisms including restriction of self-
renewing divisions, inhibition of symmetric division
and block of reprogramming of somatic/progenitor cells
into SCs.
Introduction
Since 1992, after Donehower and colleagues published
their observations on mice genetically deleted for the
p53 gene ( p53/ mice) [1], p53 has been defined as the
‘guardian of the genome’ [1,2]. More than 50 000 publica-
tions have subsequently documented the role of p53 in
mediating different cellular responses to stress stimuli,
including DNA damage (DD), ranging from transient cell
cycle arrest and DNA repair, when damage is at low levels,
to apoptosis or permanent cell cycle arrest (senescence) in
more severely damaged cells.
p53 is mutated in approximately 50% of human cancers,
whereas the remaining tumors often carry alterations of
upstream genes that ultimately lead to attenuation of its
function [3]. p53 is activated by Chk1/2, through the ATM/
ATR kinase cascade, in response to DD, telomere dysfunc-
tion or replication stress, as well as by the ARF pathway in
response to oncogenes [4]. These stimuli induce p53 upre-
gulation mainly by blocking its MDM2-dependent ubiqui-
tination and degradation [5]. Once activated, p53 acts as a
transcription factor, upregulating a series of target genes
that are involved in inhibition of the cell cycle, induction of
apoptosis or senescence, control of genomic stability and
inhibition of blood vessel formation [6]. Recently, p53 has
been shown to regulate microRNA (miRNA) processing
and also serves as an inducer of miRNA expression [7,8];
as downregulation of miRNAs is often observed in human
cancer, this is an important finding that highlights
the possibility of novel therapeutic approaches based onCorresponding author: Pelicci, P.G. (piergiuseppe.pelicci@ifom-ieo-campus.it).
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Among these p53-regulated miRNAs, the miR-34 family
appears to be strongly involved in the control of quiescence,
apoptosis and even stemness in various contexts [9]. Nota-
bly, loss of p53 correlates with decreased levels of a com-
ponent of the miR-200c family and increased expression of
epithelial–mesenchymal transition (EMT) factors, which
have been linked to the stem cell (SC) phenotype [10].
The pivotal role of p53 in cancer, and its potential use as
a therapeutic target, is confirmed by recent reports that
indicate that re-expression or reactivation of p53 in p53-
deficient or p53-defective tumors causes tumor regres-
sion in different mouse models of lymphoma, sarcomas,
hepatocarcinomas, established osteosarcoma and lym-
phoma xenografts [11–16].
Most of the observations on the many effects of p53 were
generated using established cell lines or relatively differ-
entiated primary cells. In recent years, the increased
interest in SCs combined with the idea that these cells
and/or early progenitors might be the targets of neoplastic
transformation drew attention to the role of p53 and its
tumor suppressor activities in SCs. These new studies,
while confirming some of the known functions of p53 in
SCs, have highlighted novel and unexpected roles for this
protein. This opinion article will focus on recent advances
in p53 research with regard to the regulation of the adult
SC pool in different compartments. In particular, we will
first review the role of p53 in SC reprogramming and then
we will discuss p53 functions in mammary, hematopoietic
and brain SCs, analyzing its role in the regulation of self-
renewal and asymmetric versus symmetric division. Final-
ly, we will introduce the possibility of eradicating tumors
by targeting p53 in cancer stem cells (CSCs). We will
attempt to show that p53 loss can deregulate these mech-
anisms, ultimately leading to SC increase.
p53 in induced pluripotent stem cell (iPSC)
reprogramming
Recently, p53 has been involved in the regulation of the
process of dedifferentiation (reprogramming) of somatic
cells into a pluripotent state similar to that of embryonic
stem (ES) cells [17,18]. These are termed induced pluripo-
tent stem cells (iPSCs) and can be obtained with low
efficiency (less than 1%) by the transient expression in
somatic cells of four ‘reprogramming’ genes (the Yamanaka
factors: Sox2, Oct4, Klf4 and c-myc) [19]. These cells are
virtually indistinguishable from ES cells in gene expres-
sion and epigenetic status and are able to differentiate into011.08.002 Trends in Molecular Medicine xx (2011) 1–7 1
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tion in adult mice and chimeric mice if implanted in
blastocysts [19,20]. The low efficiency of reprogramming
processes and their long latency [19] have been attributed
either to the activation of checkpoint responses leading to
senescence or apoptosis, or to the difficulty to convert
somatic cells to an epigenetic status similar to ES cells.
At least two of the four reprogramming genes (c-myc and
klf-4) are very well-known oncogenes that are able to
activate a checkpoint response. Expression of the repro-
gramming genes, inserted either in combination or alone,
induces a complex response involving upregulation of
gH2AX, p53, p21, p16 and p15 and leads to a senescent
phenotype, characterized by low BrdU incorporation, rep-
resentative of low levels of DNA replication, and high bGal
staining, indicating senescence [21,22]. Importantly, one of
the first events occurring during reprogramming seems to
be the epigenetic silencing of the ink4a locus, which
encodes p16 and p19arf. These proteins are positive reg-
ulators of the pRb and p53 tumor suppressor pathways,
respectively. However, the p53 pathway seems more rele-
vant to the reprogramming of mouse cells, whereas pRb is
more important in human cells [21,22]. Notably, telomere
shortening, which is known to induce a p53 response, is
also able to counteract the reprogramming process [23].
These observations indicate that p53 acts as a negative
regulator of the reprogramming process. The first evidence
for a role of p53 in the control of this process came from
studies on human fibroblasts in which either SV40 large T
antigen (a repressor of p53 and pRb pathways) [24] or p53
small interfering RNA (siRNA) [25] were used together
with the Yamanaka factors to improve the efficiency of
iPSC reprogramming. Subsequently, it was demonstrated
that inhibition or loss of p53 increases reprogramming
efficiency by 3- to 10-fold, depending on the cell system
or the manner of deletion or inactivation of p53 [22,23,26–
28]. The molecular mechanism(s) underlying the role of
p53 in reprogramming is still unclear. Li and colleagues
have suggested that the Yamanaka factors repress the
Ink4/Arf locus as an early event during reprogramming,
causing deactivation of both the p53 and pRb pathways
[22]. Other studies have proposed that p53 counteracts
reprogramming by activating a stress response that in turn
induces senescence [26,28] or apoptosis [23,27]. The differ-
ent responses observed in these studies could reflect a
cellular heterogeneity in the expression of reprogramming
factors. An elegant way to circumvent this problem came
from the work of the Jaenisch group [29]. In their paper,
the authors describe the setting-up of a ‘secondary system’
to obtain iPSCs. Primary iPSCs were obtained by infecting
fibroblasts with the Yamanaka factors, under the control of
a doxycycline inducible promoter, and then implanted in
blastocysts to obtain secondary chimeric mice. Secondary
pre-B cells were then isolated and plated, in the presence of
doxycycline, as single cells. Using this system, which en-
abled homogeneous factor expression, Jaenisch and collea-
gues demonstrated that virtually all the secondary cells
were able to reprogram into iPSCs, although with different
latency (3–5% of reprogramming after 2 weeks, >92% after
18 weeks). Notably, p53 knockdown accelerated the kinet-
ics of reprogramming (>93% after 8 weeks) by enhancing2the cell proliferation rate. This situation is compatible with
a model in which reprogramming proceeds through a series
of limiting steps and epigenetic changes that occur during
cell division/expansion.
Regardless of the specific mechanisms, these studies
draw attention to a novel putative role for p53 in SCs: it
might act as a barrier to reprogramming, preventing the
generation of new SCs from their differentiated progenies.
Because SCs are putative targets of cancer transformation,
the restraining activity of p53 on the number of SCs and
their direct progenies might contribute to its tumor sup-
pressive function (Figure 1). In this scenario, in tumors
where p53 is mutated or inactivated, reprogramming could
contribute to the expansion of cancer SCs. Interestingly,
neonatal (but not mature) mouse testis cells are able to
spontaneously reprogram in vitro, albeit with a very low
frequency (1 cell in 15 million), into ES-like cells [30].
Consistent with previous findings, p53 loss increases the
reprogramming frequency of neonatal cells and allows
reprogramming of mature cells. Notably, in vivo, p53/
mice show a high frequency of testicular teratoma [30].
Although there is no direct evidence of reprogramming
occurring in vivo, it is possible that some somatic cells may
reprogram into adult SCs, especially the scarcely differen-
tiated progenitor cells that have not yet accumulated many
genetic and epigenetic changes.
p53 in mammary stem cells
Adult mammary SCs can be cultured in vitro in nonad-
herent conditions as floating aggregates called mammo-
spheres [31,32]. We have recently characterized both
human [33] and mouse [34] mammospheres from normal
tissues (wild type, WT) as spherical colonies derived from
the clonal expansion of individual mammary SCs. Mam-
mospheres contain an average of 1 SC per sphere and can
be propagated over several passages of dissociation and
reformation. Despite showing self-renewal capability,
mammosphere serial replating leads to functional exhaus-
tion of WT SCs, thus indicating that they possess limited
life span in culture. In addition, direct imaging of the
initial cell division and analysis of the partitioning of
the cell fate determinant Numb has revealed that WT
mammary SCs prevalently divide through asymmetric
division [34], a specific division strategy that ensures both
SC self-renewal and differentiation. Following asymmet-
ric division in fact, one daughter cell retains SC identity,
while the other commits towards differentiation [35]. By
contrast, mammospheres derived from p53/ mice con-
tain an average of 5–6 SCs, are immortal and expand
geometrically in culture, thus showing unlimited self-
renewal potential.
In view of the accepted role of p53 in cell cycle restriction
and induction of apoptosis, the ‘immortal’ behavior or the
increased self-renewal of p53/ SCs is not entirely sur-
prising. However, the geometric expansion of the p53/
mammospheres and the 5- to 6-fold increase in the number
of SCs per sphere together strongly suggest that p53
controls the mode of SC divisions. In addition, we con-
firmed in vivo that p53/ SCs prevalently adopt a sym-
metric strategy of self-renewing divisions [34]. Notably,
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Figure 1. Role of p53 in stem cells (SCs): a possible model. (a) Somatic compartment. Different types of stress, as indicated, activate p53 that induces, in turn, cell cycle
arrest (gray line) to allow DNA repair, apoptosis or senescence (gray arrows). (b) Stem compartment. Stem cells (SCs, cyan oval cells) are able to self-renew by (i) dividing
asymmetrically (cyan arrows) to generate both a new SC and a progenitor cell (ochre oval cells), which rapidly divides (represented by overlapping cells) or (ii) by dividing
symmetrically, with less frequency (cyan arrows) to generate two SCs. Progenitor cells can become reprogrammed to generate additional SCs (blue arrows) that may
further divide symmetrically. Self-renewal, symmetric divisions and reprogramming contribute to maintain numbers of SCs (red box). p53 regulates SC numbers (red line)
by restraining self-renewal (ochre line), inhibiting SC symmetric divisions (cyan line) and blocking reprogramming of progenitors (blue lines).
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gramming of progenitor or somatic cells, as a consequence
of p53 loss; the relative contribution of reprogramming,
however, remains to be determined.
Despite the fact that p53/ mammary glands have an
increased SC pool and p53/mammary SCs geometrical-
ly expand in culture, transplantation of these cells in
recipient mice generates a normal mammary gland. Ac-
cordingly, p53/ mice, at least in the murine genetic
background C57/BL6, rarely develop mammary tumors
[34,36–39]. Nevertheless, several observations suggest
that loss of p53 is involved in the etiopathology of both
human and mouse mammary tumors: (i) mutations of p53
are found in many breast cancers and women affected by
the Li–Fraumeni syndrome (an inherited predisposition to
cancer development linked to germline mutations in
the p53 gene) often develop breast tumors [38]; (ii) in
the BALB/c background, approximately 75% of p53/
mice have microscopic lesions in the mammary gland
(sarcomas, epithelial hyperplasia and alterations in stro-
mal morphology) [40]; (iii) transplantation of the p53/
BALB/c epithelium into fat pads of WT syngeneic mice
leads to the development of mammary carcinomas in
60–75% of mice [40,41]; (iv) in a conditional mammary
tumor model, approximately 70% of mice that carrytissue-specific inactivation of p53 develop mammary carci-
nomas [42]; and (v) in ErbB2 transgenic mice, which
develop mammary carcinomas with high penetrance and
short latency, p53 impairment is responsible for the im-
mortal behavior and the geometric expansion of mammary
CSCs in vitro and for carcinoma growth in vivo [34].
In this scenario, an intriguing possibility is that p53
may carry out its tumor-suppressive function in SCs, on
the one hand, by activating canonical DNA damage
responses and, on the other hand, in the absence of any
DNA damage, by preventing the expansion of the SC pool
through the induction of an asymmetric mode of division
(Figure 1). In this context, it is worth noting that symmet-
ric divisions per se may induce aneuploidy, thus further
contributing to cancer initiation. This is the case for
Drosophila neuroblasts, which become aneuploid upon a
few rounds of symmetric divisions [43], probably because
the same machinery that controls the modality of SC
division also regulates centrosome functions, mitotic spin-
dle orientation and chromosome segregation [44,45].
p53 in hematopoietic stem cells
Hematopoietic stem cells (HSCs) are probably the best
characterized among somatic SCs, owing to the availability
of well-established cell surface markers that facilitate their3
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CD150+ CD48 population or SLAM HSC population).
Several studies have recently investigated p53 functions
in HSCs, both under steady-state conditions and in re-
sponse to various forms of cellular stress. They have shown
that expression of p53 is crucial for the regulation of
several aspects of HSC behavior, including quiescence,
self-renewal, survival, DNA repair and cell competition.
Most HSCs are noncycling under steady-state condi-
tions and maintenance of quiescence is critical for the
preservation of their function. Deletion of p53 in mice leads
to increased self-renewal of HSCs, both in culture and
in vivo, and to expansion of the HSC pool [46]. Interesting-
ly, Chen et al. found that transplantation of SLAM HSCs
from p53 null mice into lethally irradiated recipients
resulted in reduced engraftment in the second serial trans-
plantation, suggesting that the increased self-renewal of
p53 null HSCs is not associated with an increased repo-
pulating ability of individual HSCs [47]. It is not known
whether this reduction may also happen in the second
serial transplantation passage of mammary SCs, although
mammosphere serial replating experiments indicate that
loss of p53 does not reduce either self-renewal or function-
ality of mammary SCs in vitro [34]. Notably, Chen et al.
also reported that recipients of p53 null HSCs did not
develop lymphomas or other tumors, whereas transplan-
tation of the whole bone marrow (WBM) led to both en-
hanced engraftment of p53 null HSCs and lymphomas [47].
These findings might reflect the presence of tumor initiat-
ing cells in the WBM of p53 null mice. Interestingly, loss of
p53 could promote acquisition of self-renewal by early
hematopoietic progenitor cells [48], suggesting that pro-
genitor reprogramming might contribute to the increased
frequency of reconstitution and to the lymphomas of the
p53 null bone marrow.
Abrogation of oncogene-induced antiproliferative
responses in HSCs and/or progenitors represents a further
putative mechanism by which loss of p53 might contribute
to oncogenesis. Recent studies have revealed that in vari-
ous tumors (cancer of the lung, colon, prostate or bladder,
as well as melanomas and lymphomas), during the earliest
stages of cancer progression, oncogene expression is asso-
ciated with accumulation of DNA damage and activation of
a DNA damage response involving p53 and leading to
cellular senescence [49–55]. This p53-dependent cellular
response is considered to be a powerful barrier to tumor
development. Indeed, genetic evidence has demonstrated
that p53-dependent cellular senescence is able to suppress
Pten-deficient tumorigenesis in vivo [51]. The Lowe group
has recently reported that both short hairpin RNA
(shRNA)-mediated suppression and genomic deletion of
p53 induce aberrant self-renewal of myeloid progenitor
cells. In the absence of p53, expression of oncogenic KRas
under its promoter in progenitors was able to initiate and
propagate acute myeloid leukemia [56], suggesting that
p53 regulates the cellular response to oncogene expression
in progenitors. However, p53 suppression could not reverse
the Ras-induced depletion of HSCs, suggesting that loss of
p53 does not protect HSCs from oncogenic stress [56].
Yet it is not clear how SCs and progenitors respond to
DD and oncogene expression, and what is the role of p53 in4this response. Three recent papers address the issue of how
both mouse and human hematopoietic stem and progenitor
cells (HSPCs) respond to radiation-induced DD [57–59].
These studies indicate that hematopoietic cells can adopt
different means of handling DD, depending on their dif-
ferentiation stage. Surprisingly, they also show that DD
responses in mouse or human cells follow opposite routes
and unravel a different role for p53 in the DD response of
HSPCs. Mouse HSPCs (defined as lin Sca1+ cKit+ flk2)
have a unique cell intrinsic mechanism that ensures their
survival following X-ray treatment and which involves the
activation of p53 and its transcriptional target p21 and
DNA repair [58,59]. By contrast, human cord blood HSPCs
exhibit p53-dependent radiation-induced apoptosis. Here,
p53 inactivation reduces apoptosis and preserves in vivo
HSC repopulating functions but leads to reduced self-
renewal of HSCs in secondary transplants (due to accrual
of DD) [57]. It is not clear, however, whether the differences
between these two studies reflect differences between spe-
cies, between ontogenic stages or between markers used for
the isolation of stem and progenitor populations. Further
studies are needed to evaluate how p53 levels are specifi-
cally regulated in HSCs following irradiation and what
specific molecular mechanisms regulate the different DD
responses of stem and progenitor cells.
Recently, three elegant studies have highlighted a role
for p53 in regulating the competitive selection of stem and
progenitor cells (HSPCs following the stress of ionizing
radiation (IR) [59–61]. After IR, cells with lower levels/
activity of p53 outgrew those with higher levels/activity.
Notably, although cells with lower levels of p53 proliferat-
ed more rapidly, this effect was also due to non-cell-auton-
omous induction of growth arrest and expression of
senescence-related genes in the outcompeted cells with
higher p53 activity. Thus, p53-dependent cell competition
represents a putative mechanism that might contribute to
the selective expansion of early tumor cells.
p53 in neural stem cells
Both overexpression of the E6/E7 oncogenes, which leads
to inhibition of the p53 and pRb pathways, and deletion of
p53 have been reported to increase proliferation and
self-renewal of neural SCs in a neurosphere-based system
[62–64], suggesting that one of the physiological activities
of p53 is to restrain overproliferation of neural SCs by
limiting the frequency of self-renewing divisions.
This activity may contribute to the tumor suppressor
function of p53 in brain CSCs, as recently shown in glio-
blastoma multiforme (GBM), a highly invasive type of
brain tumor [65]. In this tumor type, Nanog, a homeopro-
tein required to maintain ES pluripotency [66], appears
essential for SC functions as its inactivation reduces neuro-
sphere formation in vitro and GBM growth in vivo. Impor-
tantly, in this system, p53 negatively regulates Nanog [65],
suggesting a role for p53 in the control of both CSC self-
renewal and GBM growth.
CSC-targeted treatment of tumors
Currently available antiproliferative drugs have been se-
lected for their ability to reduce tumor size in early clinical
trials; however, tumor size reduction does not necessarily
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observations suggest that both normal SCs and CSCs
are more resistant to chemotherapy than their differenti-
ated progenies. This may reflect the well-known property
of SCs and CSCs to remain quiescent or may be due to the
increased expression of antiapoptotic proteins in SCs and
CSCs, such as members of the BCL-2 family [67,68], or
transport proteins such as MDR1 and the ABC transpor-
ters [69]. Thus, it has been proposed that CSCs might
survive conventional treatments and be responsible for
tumor relapse. Accordingly, selective ablation of the rare
CSCs, probably in association with conventional antipro-
liferative drugs, is foreseen as a potentially more effective
approach to eradicate tumors.
As mentioned above, p53 is also emerging as a potential
target for therapies that could lead to CSC elimination.
Three groups have recently reported that re-expression of
p53 by different means causes regression of various p53-
null tumors. In the first report, hydroxytamoxifen-mediat-
ed activation of a p53/estrogen receptor fusion protein
caused rapid apoptosis in lymphomas and significantly
increased survival of the mice [11]. In the second study,
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Figure 2. Role of p53 in tissue homeostasis, tumor formation and tumor response to t
modifications acetylation (Ac) and phosphorylation (P) maintains normal tissue homeos
restricting SC life span. Stem cells: SCs; Pr: progenitors; gray SCs: pro-senescent SCs. (b
modifications) contributes to tumor formation and growth by increasing the frequency 
them immortality. Alternate usage of symmetric and asymmetric divisions permits 
conventional chemotherapy or radiotherapy induces tumor regression and selects for 
activity in tumors using MDM2 inhibitors (such as Nutlin) or by re-expression of wild
asymmetric and restores the CSC senescence program, leading to tumor regression.regression of spontaneous lymphomas and sarcomas via
apoptosis and senescence, respectively [15]. Finally, p53
restoration caused tumor regression in a hepatocarcinoma
xenograft model by inducing senescence and differentia-
tion [16].
In those tumors in which p53 is not mutated (50% of
human cancers [3]) but only functionally attenuated due to
the activation of p53 inhibitory pathways, pharmacological
reactivation of p53 (using Nutlin3, which inhibits binding
of p53 to Mdm2, a protein that leads to p53 degradation)
also results in tumor regression, as in the case of estab-
lished osteosarcomas and lymphoma xenografts [12–14].
Our group has used Nutlin3 to treat ErbB2 transgenic
mouse breast tumors where CSCs express low levels of p53
and the following results were found: (i) Nutlin3 selectively
reduces the number of CSCs, (ii) it induces a switch from
symmetric to asymmetric CSC division, and (iii) it reduces
tumor size by stabilizing p53 [34]. Notably, Nutlin3
exerted little or no effects on all measured properties of
WT SCs (life span, frequency of self-renewing divisions and
ability to generate proliferating progenitor cells) [34], con-
firming the generally accepted notion that only tumor cells
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reatment: a possible model. (a) Activated p53, indicated as a box with the protein
tasis by imposing a prevailing asymmetric mode of SC division (black arrows) and
) Functionally impaired, mutated or deleted p53 (indicated as a box without protein
of cancer SCs (CSCs) symmetric divisions (red arrows and star) and conferring on
tumor expansion and cancer cell differentiation. (c) Treatment of tumors with
rare resistant CSCs that are responsible for tumor relapse (left); restoration of p53
 type p53 reverts the mode of division of CSCs from prevailingly symmetric to
5
Box 1. Outstanding questions and future perspectives
 Identify reliable membrane markers to recognize and purify SCs
and CSCs.
 Identify new membrane markers capable of discriminating
symmetric versus asymmetric divisions in SCs and CSCs.
 Develop new drugs capable of restoring asymmetric divisions by
stabilizing p53.
 Define assays able to predict the outcome of a CSC targeted
therapy in both preclinical models of cancer and patients.
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Nutlin3 reverted the life span and self-renewal properties
of CSCs to those typical of WT SCs, consistent with the
observed physiological function of p53 in SCs [34]. Further
studies are now focusing on the cellular and molecular
targets of p53 restoration in different tumor types.
Concluding remarks
Recent studies designed to highlight p53 functions in SCs,
while confirming its central role in the control of cell cycle
progression, hint at the possibility that p53 is involved in
the regulation of SC homeostasis, as demonstrated by the
fact that p53-null mice show an expansion of the SC pool in
several compartments, such as blood [46], mammary
glands [34] and brain [63,64].
In view of its well-established antiproliferative effect, it
is not surprising that p53 loss also increases SC self-
renewal in these compartments [34,46,62,63]. However,
increased self-renewal alone cannot account for SC expan-
sion, if the modality of SC division remains prevalently
asymmetric. Interestingly, it has been shown that p53
controls the modality of cell division in both mouse and
human fibroblasts, as well as in adult mammary epithelial
cells, and this function might also take place in adult
SCs [70–72]. Indeed, we have recently demonstrated [34]
in vitro that p53 loss allows mammary SC symmetric
divisions and that this fact correlates in vivo with amplifi-
cation of the mammary SC pool and geometric expansion of
SCs during the life of p53 null mice. Thus, the combination
of increased self-renewal and symmetric divisions might
explain the amplification of the SC pool observed in p53
null animals. Nonetheless, it remains to be formally shown
by direct imaging that p53 loss also increases in vivo the
frequency of SC symmetric divisions and that this increase
also occurs in tissues other than the mammary gland.
The involvement of p53 in iPSC reprogramming suggests
that its loss or inactivation can induce reprogramming of
somatic cells into adult SCs, thus contributing to SC expan-
sion. However, because the vast majority of studies
have focused on the process of de-differentiation into ES
cells, direct evidence of reprogramming of progenitor/
somatic cells into adult SCs of the same compartment, or
that reprogramming can occur in vivo, is still lacking.
Regardless, these observations suggest that p53 carries
out its tumor suppression role not only via well-accepted
functions, such as cell cycle inhibition and induction of
apoptosis or senescence (Figure 1a) but also by regulating
SC homeostasis. Specifically, p53 appears able to restrain
SC self-renewal, impose an asymmetric mode of division
and block the reprogramming of somatic/progenitor cells
into SCs (Figures 1b and 2a). Thus, suppression of p53
should favor tumor formation due to the expansion of CSCs
resulting from increased self-renewal, symmetric divisions
and reprogramming (Figures 1b and 2b). On the contrary,
restabilization of p53 in CSCs should reduce SC number
and block cancer progression and growth (Figure 2c).
This assumption opens new therapeutic opportunities
aimed at restoring p53 functions in order to treat cancer
by rescuing some of the physiological properties of SCs
(Box 1). Re-establishment of p53 functions could be
achieved with new drugs able to block p53 degradation,6either through the use of mediators of p53 downstream
effects, such as specific miRNAs, or by targeting new path-
ways controlled by p53.
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